摘要
目的评价国产阿德福韦酯胶囊治疗HBeAg阳性慢性乙型肝炎患者的安全性与效果。方法采用随机对照的方法，69例HBeAg阳性慢性乙型肝炎患者经口服阿德福韦酯胶囊10mg／d（治疗组），62例口服苦参素胶囊0．6g／d（对照组），观察48周治疗期间和治疗后，血清HBADNA阴转率、丙氨酸氨基转氨酶（ALT）复常率、HBeAg阴转率、抗-HBe阳转率以及不良反应。结果治疗12周时，治疗组血清HBVDNA阴转率、ALT复常率、HBeAg阴转率、抗-HBe阳转率均高于对照组，分别为53．2％比7．8％；36．0％比8．7％；13．6％比3．1％；6．2％比0（x^2=56．32、23．18，均P〈0．01）。治疗48周时，在治疗组和对照组则分别为78．0％比9．6％；56．8％比28．7％；32．1％比11．7％；18．7％比6．3％（x^2=76．78、21．72、20．61、21．32，均P〈0．01）。结论阿德福韦酯胶囊治疗HBeAg阳性的慢性乙型肝炎的安全性与有效性均明显优于苦参素对照组。
Objective To evaluate the safety and effect of adefovir dipivoxil（ADV） on hepatitis B in HBeAg- positive patients. Methods 131 patients were divided into two groups randomly. Two groups were treated with ADV （10mg/d） and matrine（0. 6g/d） , respectively. The rate of HBV negative ,the normalization rates of ALT, HBeAg loss and anti-HBe seroconversion were evaluated respectively. Results After 12 weeks of treatment,the rate of HBV neg- ative,the normalization rates of ALT, HBeAg loss and anti-HBe seroconversion of ADV were all significantly higher than those of matrine group（53.2% vs 7.8% ,36.0% vs 8.7% , 13.6% vs 3.1% ,6.2% vs 0,respectively,x2 = 56. 32,23.18, all P 〈 0.01 ）. Conclusion The domestic ADV superior to matrine in HBeAg-positive patients.
出处
《中国基层医药》
CAS
2013年第7期986-988,共3页
Chinese Journal of Primary Medicine and Pharmacy
关键词
阿德福韦酯
肝炎
乙型
慢性
肝炎e抗原
乙型
随机对照试验
Adefovir dipivoxil
Chronie Hepatitis B
Hepatitis B virus e antigen
Randomized controlled trim
